Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study
Abstract Recovery is an important outcome of schizophrenia that has not been well defined or researched. Using a stringent definition of recovery that included long-lasting symptomatic and functional remission as well as an adequate quality of life for a minimum of 24 months and until the 36-month v...
Gespeichert in:
Veröffentlicht in: | Schizophrenia research 2009-03, Vol.108 (1), p.223-230 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 230 |
---|---|
container_issue | 1 |
container_start_page | 223 |
container_title | Schizophrenia research |
container_volume | 108 |
creator | Novick, Diego Haro, Josep Maria Suarez, David Vieta, Eduard Naber, Dieter |
description | Abstract Recovery is an important outcome of schizophrenia that has not been well defined or researched. Using a stringent definition of recovery that included long-lasting symptomatic and functional remission as well as an adequate quality of life for a minimum of 24 months and until the 36-month visit, we determined the frequency and predictors of recovery in patients with schizophrenia during 3 years of antipsychotic treatment in the prospective, observational Schizophrenia Outpatients Health Outcomes (SOHO) study. Of the 6642 patients analysed, 33% achieved long-lasting symptomatic remission, 13% long-lasting functional remission, 27% long-lasting adequate quality of life, and 4% achieved recovery during the 3 year follow-up period. Logistic regression analysis revealed that social functioning at study entry (having good occupational/vocational status, living independently and being socially active) and adherence with medication were factors significantly associated with achieving recovery. Higher negative symptom severity, higher BMI and lack of effectiveness as the reason for change of medication at baseline were baseline factors associated with a lower likelihood of achieving recovery. Treatment with olanzapine was also associated with a higher frequency of recovery compared with risperidone, quetiapine, typical antipsychotics (oral, depot) and patients taking two or more antipsychotic medications. There were no differences among the patients taking olanzapine, clozapine and amisulpride. Predictors of long-lasting symptomatic remission, functional remission and adequate quality of life were also independently analysed. Although the results should be interpreted conservatively due to the observational, non-randomised study design, they indicate that only a small proportion of patients with schizophrenia achieve recovery and suggest that social functioning, medication adherence and type of antipsychotic are important predictors of recovery. |
doi_str_mv | 10.1016/j.schres.2008.11.007 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66943939</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0920996408005161</els_id><sourcerecordid>66943939</sourcerecordid><originalsourceid>FETCH-LOGICAL-c511t-ac507ab53a95cfe135a5015712e9fe1b74d94274d6ea20515520622ba21d9b5c3</originalsourceid><addsrcrecordid>eNqFklGLEzEUhYMobq3-A5G8KPow9d5MM9P4IMiiVlgoWH0Omcwdmzoz6SaZhfrrTW1ZwRcJJCScc-7Nx2XsOcICAau3-0W0u0BxIQBWC8QFQP2AzVDWZSEkqIdsBkpAoVS1vGJPYtwDAEqoH7MrVFCDUjhj6StZf0fhyN3I0464n9LBJEdj4pFScuOPd7ysisGPacdzualPkXfBD3_UW7tzv_wh9zE6wzf33sjXZPrsyE_WDxT56-1mvXnDY5ra41P2qDN9pGeXc86-f_r47Xpd3Gw-f7n-cFNYiZgKY3O3ppGlUdJ2hKU0Mv-gRkEqX5t62aqlyHtFRoBEKQVUQjRGYKsaacs5e3XOPQR_O1FMenDRUt-bkfwUdVWpZanymrPlWWiDjzFQpw_BDSYcNYI-0dZ7faatT7Q1os60s-3FJX9qBmr_mi54s-DlRWCiNX0XzGhdvNcJFJVaraqse3_WUaZx5yjkahmjpdYFskm33v2vk38DbO9Gl2v-pCPFvZ_CmElr1FFo0NvTZJwGA1aQwVVY_gYAn7Tc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>66943939</pqid></control><display><type>article</type><title>Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Novick, Diego ; Haro, Josep Maria ; Suarez, David ; Vieta, Eduard ; Naber, Dieter</creator><creatorcontrib>Novick, Diego ; Haro, Josep Maria ; Suarez, David ; Vieta, Eduard ; Naber, Dieter</creatorcontrib><description>Abstract Recovery is an important outcome of schizophrenia that has not been well defined or researched. Using a stringent definition of recovery that included long-lasting symptomatic and functional remission as well as an adequate quality of life for a minimum of 24 months and until the 36-month visit, we determined the frequency and predictors of recovery in patients with schizophrenia during 3 years of antipsychotic treatment in the prospective, observational Schizophrenia Outpatients Health Outcomes (SOHO) study. Of the 6642 patients analysed, 33% achieved long-lasting symptomatic remission, 13% long-lasting functional remission, 27% long-lasting adequate quality of life, and 4% achieved recovery during the 3 year follow-up period. Logistic regression analysis revealed that social functioning at study entry (having good occupational/vocational status, living independently and being socially active) and adherence with medication were factors significantly associated with achieving recovery. Higher negative symptom severity, higher BMI and lack of effectiveness as the reason for change of medication at baseline were baseline factors associated with a lower likelihood of achieving recovery. Treatment with olanzapine was also associated with a higher frequency of recovery compared with risperidone, quetiapine, typical antipsychotics (oral, depot) and patients taking two or more antipsychotic medications. There were no differences among the patients taking olanzapine, clozapine and amisulpride. Predictors of long-lasting symptomatic remission, functional remission and adequate quality of life were also independently analysed. Although the results should be interpreted conservatively due to the observational, non-randomised study design, they indicate that only a small proportion of patients with schizophrenia achieve recovery and suggest that social functioning, medication adherence and type of antipsychotic are important predictors of recovery.</description><identifier>ISSN: 0920-9964</identifier><identifier>EISSN: 1573-2509</identifier><identifier>DOI: 10.1016/j.schres.2008.11.007</identifier><identifier>PMID: 19070991</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>Adolescent ; Adult ; Adult and adolescent clinical studies ; Antipsychotic Agents - therapeutic use ; Antipsychotics ; Biological and medical sciences ; Clinical outcome ; Female ; Humans ; International Cooperation ; Logistic Models ; Longitudinal Studies ; Male ; Medical sciences ; Middle Aged ; Neuropharmacology ; Observation - methods ; Outcome Assessment (Health Care) - statistics & numerical data ; Outpatients ; Pharmacology. Drug treatments ; Psychiatry ; Psycholeptics: tranquillizer, neuroleptic ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Psychopharmacology ; Psychoses ; Quality of Life ; Recovery ; Recovery of Function - drug effects ; Recovery of Function - physiology ; Recurrence ; Schizophrenia ; Schizophrenia - drug therapy ; Schizophrenic Psychology ; Sensitivity and Specificity ; Time Factors ; Treatment Outcome</subject><ispartof>Schizophrenia research, 2009-03, Vol.108 (1), p.223-230</ispartof><rights>Elsevier B.V.</rights><rights>2008 Elsevier B.V.</rights><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c511t-ac507ab53a95cfe135a5015712e9fe1b74d94274d6ea20515520622ba21d9b5c3</citedby><cites>FETCH-LOGICAL-c511t-ac507ab53a95cfe135a5015712e9fe1b74d94274d6ea20515520622ba21d9b5c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0920996408005161$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21269886$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19070991$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Novick, Diego</creatorcontrib><creatorcontrib>Haro, Josep Maria</creatorcontrib><creatorcontrib>Suarez, David</creatorcontrib><creatorcontrib>Vieta, Eduard</creatorcontrib><creatorcontrib>Naber, Dieter</creatorcontrib><title>Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study</title><title>Schizophrenia research</title><addtitle>Schizophr Res</addtitle><description>Abstract Recovery is an important outcome of schizophrenia that has not been well defined or researched. Using a stringent definition of recovery that included long-lasting symptomatic and functional remission as well as an adequate quality of life for a minimum of 24 months and until the 36-month visit, we determined the frequency and predictors of recovery in patients with schizophrenia during 3 years of antipsychotic treatment in the prospective, observational Schizophrenia Outpatients Health Outcomes (SOHO) study. Of the 6642 patients analysed, 33% achieved long-lasting symptomatic remission, 13% long-lasting functional remission, 27% long-lasting adequate quality of life, and 4% achieved recovery during the 3 year follow-up period. Logistic regression analysis revealed that social functioning at study entry (having good occupational/vocational status, living independently and being socially active) and adherence with medication were factors significantly associated with achieving recovery. Higher negative symptom severity, higher BMI and lack of effectiveness as the reason for change of medication at baseline were baseline factors associated with a lower likelihood of achieving recovery. Treatment with olanzapine was also associated with a higher frequency of recovery compared with risperidone, quetiapine, typical antipsychotics (oral, depot) and patients taking two or more antipsychotic medications. There were no differences among the patients taking olanzapine, clozapine and amisulpride. Predictors of long-lasting symptomatic remission, functional remission and adequate quality of life were also independently analysed. Although the results should be interpreted conservatively due to the observational, non-randomised study design, they indicate that only a small proportion of patients with schizophrenia achieve recovery and suggest that social functioning, medication adherence and type of antipsychotic are important predictors of recovery.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Adult and adolescent clinical studies</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>Antipsychotics</subject><subject>Biological and medical sciences</subject><subject>Clinical outcome</subject><subject>Female</subject><subject>Humans</subject><subject>International Cooperation</subject><subject>Logistic Models</subject><subject>Longitudinal Studies</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neuropharmacology</subject><subject>Observation - methods</subject><subject>Outcome Assessment (Health Care) - statistics & numerical data</subject><subject>Outpatients</subject><subject>Pharmacology. Drug treatments</subject><subject>Psychiatry</subject><subject>Psycholeptics: tranquillizer, neuroleptic</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Psychoses</subject><subject>Quality of Life</subject><subject>Recovery</subject><subject>Recovery of Function - drug effects</subject><subject>Recovery of Function - physiology</subject><subject>Recurrence</subject><subject>Schizophrenia</subject><subject>Schizophrenia - drug therapy</subject><subject>Schizophrenic Psychology</subject><subject>Sensitivity and Specificity</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><issn>0920-9964</issn><issn>1573-2509</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFklGLEzEUhYMobq3-A5G8KPow9d5MM9P4IMiiVlgoWH0Omcwdmzoz6SaZhfrrTW1ZwRcJJCScc-7Nx2XsOcICAau3-0W0u0BxIQBWC8QFQP2AzVDWZSEkqIdsBkpAoVS1vGJPYtwDAEqoH7MrVFCDUjhj6StZf0fhyN3I0464n9LBJEdj4pFScuOPd7ysisGPacdzualPkXfBD3_UW7tzv_wh9zE6wzf33sjXZPrsyE_WDxT56-1mvXnDY5ra41P2qDN9pGeXc86-f_r47Xpd3Gw-f7n-cFNYiZgKY3O3ppGlUdJ2hKU0Mv-gRkEqX5t62aqlyHtFRoBEKQVUQjRGYKsaacs5e3XOPQR_O1FMenDRUt-bkfwUdVWpZanymrPlWWiDjzFQpw_BDSYcNYI-0dZ7faatT7Q1os60s-3FJX9qBmr_mi54s-DlRWCiNX0XzGhdvNcJFJVaraqse3_WUaZx5yjkahmjpdYFskm33v2vk38DbO9Gl2v-pCPFvZ_CmElr1FFo0NvTZJwGA1aQwVVY_gYAn7Tc</recordid><startdate>20090301</startdate><enddate>20090301</enddate><creator>Novick, Diego</creator><creator>Haro, Josep Maria</creator><creator>Suarez, David</creator><creator>Vieta, Eduard</creator><creator>Naber, Dieter</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20090301</creationdate><title>Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study</title><author>Novick, Diego ; Haro, Josep Maria ; Suarez, David ; Vieta, Eduard ; Naber, Dieter</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c511t-ac507ab53a95cfe135a5015712e9fe1b74d94274d6ea20515520622ba21d9b5c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Adult and adolescent clinical studies</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>Antipsychotics</topic><topic>Biological and medical sciences</topic><topic>Clinical outcome</topic><topic>Female</topic><topic>Humans</topic><topic>International Cooperation</topic><topic>Logistic Models</topic><topic>Longitudinal Studies</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neuropharmacology</topic><topic>Observation - methods</topic><topic>Outcome Assessment (Health Care) - statistics & numerical data</topic><topic>Outpatients</topic><topic>Pharmacology. Drug treatments</topic><topic>Psychiatry</topic><topic>Psycholeptics: tranquillizer, neuroleptic</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Psychoses</topic><topic>Quality of Life</topic><topic>Recovery</topic><topic>Recovery of Function - drug effects</topic><topic>Recovery of Function - physiology</topic><topic>Recurrence</topic><topic>Schizophrenia</topic><topic>Schizophrenia - drug therapy</topic><topic>Schizophrenic Psychology</topic><topic>Sensitivity and Specificity</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Novick, Diego</creatorcontrib><creatorcontrib>Haro, Josep Maria</creatorcontrib><creatorcontrib>Suarez, David</creatorcontrib><creatorcontrib>Vieta, Eduard</creatorcontrib><creatorcontrib>Naber, Dieter</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Schizophrenia research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Novick, Diego</au><au>Haro, Josep Maria</au><au>Suarez, David</au><au>Vieta, Eduard</au><au>Naber, Dieter</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study</atitle><jtitle>Schizophrenia research</jtitle><addtitle>Schizophr Res</addtitle><date>2009-03-01</date><risdate>2009</risdate><volume>108</volume><issue>1</issue><spage>223</spage><epage>230</epage><pages>223-230</pages><issn>0920-9964</issn><eissn>1573-2509</eissn><abstract>Abstract Recovery is an important outcome of schizophrenia that has not been well defined or researched. Using a stringent definition of recovery that included long-lasting symptomatic and functional remission as well as an adequate quality of life for a minimum of 24 months and until the 36-month visit, we determined the frequency and predictors of recovery in patients with schizophrenia during 3 years of antipsychotic treatment in the prospective, observational Schizophrenia Outpatients Health Outcomes (SOHO) study. Of the 6642 patients analysed, 33% achieved long-lasting symptomatic remission, 13% long-lasting functional remission, 27% long-lasting adequate quality of life, and 4% achieved recovery during the 3 year follow-up period. Logistic regression analysis revealed that social functioning at study entry (having good occupational/vocational status, living independently and being socially active) and adherence with medication were factors significantly associated with achieving recovery. Higher negative symptom severity, higher BMI and lack of effectiveness as the reason for change of medication at baseline were baseline factors associated with a lower likelihood of achieving recovery. Treatment with olanzapine was also associated with a higher frequency of recovery compared with risperidone, quetiapine, typical antipsychotics (oral, depot) and patients taking two or more antipsychotic medications. There were no differences among the patients taking olanzapine, clozapine and amisulpride. Predictors of long-lasting symptomatic remission, functional remission and adequate quality of life were also independently analysed. Although the results should be interpreted conservatively due to the observational, non-randomised study design, they indicate that only a small proportion of patients with schizophrenia achieve recovery and suggest that social functioning, medication adherence and type of antipsychotic are important predictors of recovery.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>19070991</pmid><doi>10.1016/j.schres.2008.11.007</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0920-9964 |
ispartof | Schizophrenia research, 2009-03, Vol.108 (1), p.223-230 |
issn | 0920-9964 1573-2509 |
language | eng |
recordid | cdi_proquest_miscellaneous_66943939 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete |
subjects | Adolescent Adult Adult and adolescent clinical studies Antipsychotic Agents - therapeutic use Antipsychotics Biological and medical sciences Clinical outcome Female Humans International Cooperation Logistic Models Longitudinal Studies Male Medical sciences Middle Aged Neuropharmacology Observation - methods Outcome Assessment (Health Care) - statistics & numerical data Outpatients Pharmacology. Drug treatments Psychiatry Psycholeptics: tranquillizer, neuroleptic Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Psychopharmacology Psychoses Quality of Life Recovery Recovery of Function - drug effects Recovery of Function - physiology Recurrence Schizophrenia Schizophrenia - drug therapy Schizophrenic Psychology Sensitivity and Specificity Time Factors Treatment Outcome |
title | Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T16%3A07%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Recovery%20in%20the%20outpatient%20setting:%2036-month%20results%20from%20the%20Schizophrenia%20Outpatients%20Health%20Outcomes%20(SOHO)%20study&rft.jtitle=Schizophrenia%20research&rft.au=Novick,%20Diego&rft.date=2009-03-01&rft.volume=108&rft.issue=1&rft.spage=223&rft.epage=230&rft.pages=223-230&rft.issn=0920-9964&rft.eissn=1573-2509&rft_id=info:doi/10.1016/j.schres.2008.11.007&rft_dat=%3Cproquest_cross%3E66943939%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=66943939&rft_id=info:pmid/19070991&rft_els_id=S0920996408005161&rfr_iscdi=true |